Pharsight

Lupin patents expiration

1. Antara (micronized) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026281 LUPIN Treating metabolic syndrome with fenofibrate
Apr, 2025

(1 year, 6 months from now)

US9314447 LUPIN Reduced dose pharmaceutical compositions of fenofibrate
May, 2033

(9 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 30 November, 2004

Treatment: Treating severe hypertriglyceridemia; Treating primary hypercholesterolemia and mixed dyslipidemia

Dosage: CAPSULE;ORAL

How can I launch a generic of ANTARA (MICRONIZED) before it's drug patent expiration?
More Information on Dosage

ANTARA (MICRONIZED) family patents

Family Patents

2. Sesquient patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US7635773 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US8410077 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9200088 LUPIN Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9493582 LUPIN Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Drugs and Companies using FOSPHENYTOIN SODIUM ingredient

Market Authorisation Date: 05 November, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

SESQUIENT family patents

Family Patents

3. Solosec patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857133 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11324721 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(11 years from now)

US11602522 LUPIN Secnidazole for use in the treatment of sexually transmitted infection
Sep, 2035

(11 years from now)

US10335390 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11000507 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11020377 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11000508 LUPIN Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(11 years from now)

US10682338 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US10849884 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

US11684607 LUPIN Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 15, 2022
New Indication (I) Jun 30, 2024
New Patient Population (NPP) Jan 26, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 15, 2027

Drugs and Companies using SECNIDAZOLE ingredient

NCE-1 date: 2026-09-15

Market Authorisation Date: 15 September, 2017

Treatment: Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in adults; Treatment of trichomoniasis in pa...

Dosage: GRANULE;ORAL

More Information on Dosage

SOLOSEC family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic